A carregar...
The Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond
Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of meta...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MedReviews, LLC
2006
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1578715/ https://ncbi.nlm.nih.gov/pubmed/17021642 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|